vadimezan has been researched along with npi 2358 in 1 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (npi 2358) | Trials (npi 2358) | Recent Studies (post-2010) (npi 2358) |
---|---|---|---|---|---|
272 | 16 | 101 | 36 | 4 | 31 |
Protein | Taxonomy | vadimezan (IC50) | npi 2358 (IC50) |
---|---|---|---|
Tubulin alpha-1A chain | Sus scrofa (pig) | 1.8 | |
Tubulin beta chain | Sus scrofa (pig) | 1.8 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 8.9 | |
Mitogen-activated protein kinase 10 | Rattus norvegicus (Norway rat) | 6.8 | |
Tubulin beta-2B chain | Bos taurus (cattle) | 2.4 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Castaldo, V; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Sacco, PC | 1 |
1 review(s) available for vadimezan and npi 2358
Article | Year |
---|---|
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diketopiperazines; Endothelial Cells; Humans; Imidazoles; Lung Neoplasms; Pericytes; Piperazines; Stilbenes; Sulfonamides; Xanthones | 2009 |